We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

117 hedge funds and large institutions have $605M invested in KalVista Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 44 increasing their positions, 16 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 18

175% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 16

100% more capital invested

Capital invested by funds: $303M → $605M (+$302M)

43% more funds holding

Funds holding: 82 → 117 (+35)

5.7% more ownership

Funds ownership: 91.33% → 97.03% (+5.7%)

57% less call options, than puts

Call options by funds: $3.59M | Put options by funds: $8.29M

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
117
Holders Change
+35
Holders Change %
+42.68%
% of All Funds
2.05%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
54
Increased
44
Reduced
16
Closed
18
Calls
$3.59M
Puts
$8.29M
Net Calls
-$4.7M
Net Calls Change
-$3.62M

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$26.8M
2
PCH
Polar Capital Holdings
United Kingdom
+$26.5M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$25.6M
4
Franklin Resources
Franklin Resources
California
+$23.3M
5
CAM
Cormorant Asset Management
Massachusetts
+$19.7M

Top Sellers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
-$25.7M
2
IC
Ikarian Capital
Texas
-$20.2M
3
LGM
Logos Global Management
California
-$9.3M
4
OM
Opaleye Management
Massachusetts
-$8.93M
5
EAM
Eventide Asset Management
Massachusetts
-$8.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$5.76M +$5.89M +224,059 New
American Century Companies
27
American Century Companies
Missouri
$5.61M +$5.73M +218,163 New
CC
28
Commodore Capital
New York
$5.51M +$5.64M +214,467 New
IBT
29
International Biotechnology Trust
United Kingdom
$5.49M +$975K +37,100 +21%
Renaissance Technologies
30
Renaissance Technologies
New York
$3.94M +$2.73M +104,000 +210%
ACM
31
Altium Capital Management
New York
$3.29M +$3.37M +128,130 New
LCM
32
Laurion Capital Management
New York
$3.08M +$3.15M +120,000 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.84M +$1.71M +65,175 +144%
EI
34
EAM Investors
California
$2.74M +$2.81M +106,777 New
AAA
35
Affinity Asset Advisors
New York
$2.57M +$1.45M +55,000 +122%
MWNA
36
Marshall Wace North America
New York
$2.52M +$2.58M +98,178 New
Two Sigma Investments
37
Two Sigma Investments
New York
$2.07M +$1.37M +52,277 +184%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$1.7M -$251K -9,563 -13%
EGI
39
EAM Global Investors
California
$1.66M +$1.7M +64,603 New
DCM
40
DAFNA Capital Management
California
$1.5M +$1.54M +58,600 New
Goldman Sachs
41
Goldman Sachs
New York
$1.4M +$1.16M +44,029 +417%
N
42
Nuveen
North Carolina
$1.3M -$19.7K -748 -0.9%
PPA
43
Parametric Portfolio Associates
Washington
$1.29M +$1.32M +50,244 New
SCM
44
Silverarc Capital Management
Massachusetts
$1.28M +$1.31M +50,000 New
TCM
45
Tekla Capital Management
Massachusetts
$1.28M +$1.31M +50,000 New
Jacobs Levy Equity Management
46
Jacobs Levy Equity Management
New Jersey
$1.23M -$152K -5,796 -11%
Ensign Peak Advisors
47
Ensign Peak Advisors
Utah
$1.21M +$772K +29,386 +166%
Charles Schwab
48
Charles Schwab
California
$1.21M +$350K +13,310 +40%
Citadel Advisors
49
Citadel Advisors
Florida
$1.17M +$1.19M +45,411 New
SFI
50
Susquehanna Fundamental Investments
Pennsylvania
$1.04M +$305K +11,600 +40%
1
2
3 4 5

KALV Hedge Fund Activity: Q1 2021 in Review

117 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2021, worth a combined $605M — up 100% from $303M a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new KALV positions and 18 closed out — a net gain of 36 holders — while 44 added to existing stakes and 16 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $26.8M. The largest seller was SV Health Investors, exiting entirely with an estimated $25.7M sold.

  • 117 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2021, up from 82 in Q4 2020.
  • Funds reported $605M of KalVista Pharmaceuticals stock for Q1 2021, up 100% quarter-over-quarter.
  • 54 funds opened new KalVista Pharmaceuticals positions in Q1 2021 and 18 closed out, a net change of +36 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2021 was Deerfield Management, an estimated $26.8M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2021 was SV Health Investors, an estimated $25.7M sold.

Based on aggregated 13F filings for Q1 2021.